Perindopril

Iz Wikipedije, slobodne enciklopedije
Idi na navigaciju Idi na pretragu
Perindopril
(IUPAC) ime
(2S,3aS,7aS)-1-[(2S)-2- {[(2S)-1-etoksi-1-oksopentan-2-il]amino}propanoil]-oktahidro-1H-indol-2-karboksilna kiselina
Klinički podaci
Robne marke Coversyl, Coversum, Preterax, Aceon
AHFS/Drugs.com Monografija
MedlinePlus a602017
Identifikatori
CAS broj 82834-16-0
ATC kod C09AA04
C09BA04 (sa diureticima)
C09BB04 (sa amlodipinom)
PubChem[1][2] 107807
DrugBank DB00790
ChemSpider[3] 96956
UNII 1964X464OJ YesY
KEGG[4] D03753 YesY
ChEBI CHEBI:8024 YesY
ChEMBL[5] CHEMBL1581 YesY
Hemijski podaci
Formula C19H32N2O5 
Mol. masa 368,468 g/mol
SMILES eMolekuli & PubHem
Farmakokinetički podaci
Bioraspoloživost 24%
Vezivanje za proteine plazme 20%
Metabolizam Renal
Poluvreme eliminacije 1–17 sati za perindoprilat (aktivni metabolit)
Farmakoinformacioni podaci
Trudnoća D(US)
Pravni status -only (SAD)
Način primene Oralno

Perindopril je dugotrajni ACE inhibitor. On se koristi za tretman visokog krvnog pritiska, zatajenja srca i koronarne arterijske bolesti[6] u obliku perindopril arginina (Coversyl, Coversum) ili perindopril erbumina (Aceon). Ova dva preparata su terapeutski ekvivalentna.[7]

Reference[uredi - уреди | uredi izvor]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. PMID 20331846. doi:10.1186/1758-2946-2-3.  edit
  4. Joanne Wixon, Douglas Kell (2000). "Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG". Yeast 17 (1): 48–55. doi:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H. 
  5. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. PMID 21948594. doi:10.1093/nar/gkr777.  edit
  6. Royal Australian College of General Practitioners. "Consumer Medicine Information, GenRx Perindopril". Clinical Resources, Medicine information for health professionals. Arhivirano iz originala 2007-09-01. http://web.archive.org/web/20070901023153/http://www.racgp.org.au/cmi/gxcperin.pdf. 
  7. Australian Government Department of Health and Ageing (2008). "PBS For Health Professionals". Pharmaceutical Benefits Scheme. http://www.pbs.gov.au/html/healthpro/search/results?term=perindopril&scope=PBS+STATIC&form-type=simple. pristupljeno 4. 9. 2008.. 

Reference[uredi - уреди | uredi izvor]

  • Bounhoure JP, Bottineau G, Lechat P, et al.. "Value of perindopril in the treatment of chronic congestive heart failure: multicentre double-blind placebo-controlled study." Clin Exp Hypertens. 1989;A11(suppl 2):575-586.
  • Lechat P, Granham SP, Desche P, et al.. "Efficacy and acceptability of perindopril in mild-to-moderate chronic congestive heart failure." Am Heart J. 1993;126:798-806.
  • Morgan T and Anderson A; "Clinical efficacy of perindopril in hypertension." Clin Exp Pharmacol Physiol. 1992;19:61-65.
  • Myers MG; (on behalf of the perindopril multicentre dose-response study group) "A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24h after dosing." Can J Cardiol. 1996;12:1191-1196.
  • "The European trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo controlled, multicentre trial (the EUROPA study)." The Lancet 2003;362:782-788.

Spoljašnje veze[uredi - уреди | uredi izvor]

Star of life.svg Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini).